These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24265406)

  • 1. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
    Burger RA
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
    González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
    J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
    Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
    Aravantinos G; Pectasides D
    J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
    McCann GA; Smith B; Backes FJ; Rath K; Chacko S; Salani R; Eisenhauer E; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2012 Nov; 127(2):362-6. PubMed ID: 22885866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
    Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
    Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Monk BJ; Minion LE; Coleman RL
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.